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Introduction: The hemoglobin FSD is very uncommon in newborn screening programs for
sickle cell disease. In the program of Minas Gerais, Brazil, the clinical course of children
with hemoglobin SD was observed to be heterogeneous. The objective of this study was
to  estimate the incidence (1999–2012) and to describe the natural history of a cohort of
newborns with hemoglobin SD.
Methods: Isoelectric focusing was the primary method used in newborn screening. Poly-
merase chain reaction-restriction fragment length polymorphism and gene sequencing
were  used to identify mutant alleles and for haplotyping. Gap-polymerase chain reaction
was used to detect alpha-thalassemia.
Results: Eleven cases of hemoglobin S/D-Punjab and eight of Hb S-Korle Bu were detected.
Other variants with hemoglobin D mobility were not identiﬁed. All hemoglobin D-Punjab
and hemoglobin Korle Bu alleles were associated with haplotype I. Among the children with
hemoglobin S/D-Punjab, there were four with the S CAR haplotype, six with the Benin
haplotype, and one atypical. Results of laboratory tests for hemoglobin S/D-Punjab and
hemoglobin S-Korle Bu were: hemoglobin 8.0 and 12.3 g/dL (p-value <0.001), leukocyte count
13.9  × 109/L and 10.5 × 109/L (p-value = 0.003), reticulocytes 7.5% and 1.0% (p-value <0.001),
hemoglobin F concentration 16.1% and 6.9% (p-value = 0.001) and oxygen saturation 91.9%
and 97% (p-value = 0.002), respectively. Only hemoglobin S/D-Punjab children had acute pain
crises and needed blood transfusions or hydroxyurea. Those with the Benin S haplotype had
higher  total hemoglobin and hemoglobin F concentrations compared to the CAR haplotype.
Transcranial Doppler was normal in all children.
Conclusion: The clinical course and blood cell counts of children with hemoglobin S/D-Punjab
were very similar to those of hemoglobin SS children. In contrast, children with hemoglobin
S-Korle Bu had clinical course and blood cell counts like children with the sickle cell trait.
©  2016 Associac¸a˜o Bra
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Figure 1 – Molecular detection of mutations in Hb D-Punjab
and Hb Korle Bu. (A) Polymerase chain reaction-restriction
fragment length polymorphism with EcoRI in ﬁve children
with Hb D-Punjab. Patients 1, 2, and 4 had wild alleles (two
bands of 300 and 272 base pairs) and Patients 3 and 5 had
an additional band of 572 base pairs that indicates a
heterozygous mutation in the codon 121 of HBB (Hb
D-Punjab); (B) electropherogram of a child with Hb Korle Bu.
The arrow points to the heterozygous mutation
HBB:c.220G>A (GAT>AAT; Asp>Asn) detected through gene
sequencing.rev bras hematol hemot
ntroduction
ickle cell disease (SCD) is a public health problem world-
ide. The hemoglobin (Hb) SD subtype seems to be very
are. It includes the Hb S/D-Punjab variant that apparently
s associated with a more  severe clinical course, and other
b S-non-Punjab variants, with limited information regarding
aboratory and clinical data.1–3
The Hb D-Punjab variant is the most common D-subtype
escribed in the literature worldwide. It was ﬁrst described in
951 by Itano.4 It results from the replacement of the amino
cid glutamate with glutamine at position 121 of the beta-
lobin chain [beta 121(GH4) Glu>Gln; HBB: c.364G>C].
Another variant within the window of Hb D using isoelec-
ric focalization (IEF), but not using high-performance liquid
hromatography (HPLC), is Hb Korle Bu, which results from
he replacement of the amino acid aspartate with asparagine
t position 72 of the beta-globin chain [beta 73(E17) Asp>Asn;
BB: c.220G>A]. It originates from the western region of Africa,
nd its dissemination to America is probably linked to the
lave trade in the 17th to 19th centuries.5
The clinical course of patients with Hb SD disease seems
o be heterogeneous, depending on the Hb D variant. This
uggests that the sickling process is likely the result of the
nteraction between the intracellular Hb S and Hb D variants.
his interaction may be strengthened or weakened, depend-
ng on the Hb variant co-inherited with the S mutation.6–14
hildren with Hb S/D-Punjab disease seem to present a
linical course similar to those with homozygous Hb SS
isease.8,10,11,15,16
Thus, patients with Hb S/D-Punjab disease should receive
he same treatment protocol as those with Hb SS disease
ecause they may also experience potentially fatal compli-
ations during their lives.10,11,17 The use of hydroxyurea in
hildren with Hb SD disease has been restricted to isolated
ases.11,18,19
The objective of this study was to estimate the incidence
nd to describe the natural history of newborns with the Hb
D pattern by IEF, screened as part of the Neonatal Screening
rogram in the Brazilian state of Minas Gerais (PTN-MG). Addi-
ionally, beta-globin cluster haplotypes for the S, D-Punjab and
Korle Bu mutations were determined in order to try to trace the
rigin of the respective mutations.
ethods
his descriptive study is based on a retrospective cohort.
rchived medical records from the Fundac¸ão Hemominas
Government Blood Center) and the PTN-MG databank were
sed. IEF of dried blood spot samples (Neonatal Hemoglobin
esolve Screen Kit, PerkinElmer Life and Analytical Sciences,
inland) has been the primary method of newborn screening
t PTN-MG. Allele-speciﬁc polymerase chain reaction (PCR) for
A, S, C, and D-Punjab alleles was introduced in the blood
ank protocol as a conﬁrmatory test in 2010.
The population initially comprised 21 children with Hb FSD
t birth. Hb FSD means that the children were born with three
b fractions: Hb F (the major fraction at birth that steadilydecreases over the ﬁrst year of life), Hb S, and an Hb with a
zone D mobility in electrophoresis. They were born between
January 1, 1999 and December 31, 2012; a total of 3,590,315
children were screened in this period. The patients’ clinical
and laboratory data up to December 31, 2014 were reviewed so
that all children, except two, had been followed up for at least
two years.
Two patients were excluded from the clinical and molecular
analyses because ethylenediaminetetraacetic acid (EDTA)-
anticoagulated blood samples had not been obtained for
molecular tests: one child moved abroad and another moved
out of the state. Contact with the families has failed thus far.
These children were used only to calculate the incidence of Hb
SD in the cohort.
Fragments of the beta-globin gene (HBB) containing
exon 3 (forward primer 5′-TCATGCCTCTTTGCACCATTC-3′;
reverse primer 5′-CACTGACCTCCCACATTCCC-3′) were ampli-
ﬁed using PCR, and polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) was conducted
with the EcoRI enzyme to detect the D-Punjab allele (Figure 1A).
If the reaction was negative, the three exons of the HBB gene
were sequenced to identify the mutation underlying the other
Hb variants (primer composition available on request). DNA
sequencing was done in an ABI 3130 capillary sequencer
(Applied Biosystems, Foster City, CA, USA). Figure 1B illus-
trates the gene sequencing of the region in which the HBB:
c.220G>A mutation underlying Hb Korle Bu is located. Detec-
tion of seven more  common HBA deletions was carried out by
multiplex gap-PCR.20
oter.242  rev bras hematol hem
The -globin gene cluster haplotyping was carried out by
PCR-RFLP of six restriction sites: HindIII in the IVS-II of G
(rs113425530), HindIII in the IVS-II of A (rs28440105), HincII
in  (rs10128556), HincII 3′ to  (without rs), HinfI 5′ to 
(rs16911905), and HinfI 3′ to  (rs10837631). Additionally, HincII
5′ to  (rs3834466) and AvaII at IVS-II-16 of  (rs10768683) were
determined by gene sequencing. Restriction enzymes used for
the haplotype analyses were purchased from New England
Biolabs, Inc. (Beverly, MA,  USA). Classiﬁcation of haplotypes
was based on Orkin et al.21 and Nagel et al. for the S gene.22
The assignment of speciﬁc haplotypes in heterozygous states
should be interpreted with caution if family studies or allele
cloning are not performed. In the present study, the inter-
pretation of the results was facilitated by our previous report
showing that in 206 Hb SS children from Minas Gerais, 98.5%
of the S chromosomes were of the types CAR or Ben.23
A Coulter T-890 hematology counter was used to perform
all blood cell counts. Reticulocytes were counted in blood
smears stained with brilliant cresyl blue. All hematologi-
cal values were transcribed from the medical records in the
absence of acute clinical manifestations and at least three
months after the use of blood products. The mathematical
average of each item was considered as the baseline value for
each patient. The relative baseline concentration of Hb F was
obtained from the Hb electrophoresis results reported in each
patient’s medical record. The results of electrophoresis test-
ing performed at the oldest age possible within the follow-up
period were used as long as the sample had been collected
after two years of age.
Transcranial Doppler (TCD) examinations were performed
in 14 children and interpreted by a single expert using a Nico-
let equipment (model EME  TC 2000, Nicolet, Madison, WI,
USA). High-risk TCD was deﬁned as a time-averaged mean
of the maximum velocity (TAMMX) ≥200 cm/s in the internal
carotid or middle cerebral artery as originally deﬁned by stroke
prevention in sickle cell anemia (STOP) investigators.24 The
examination could not be performed in ﬁve patients: three
examinations were impossible because of the lack of cooper-
ation on the part of the children and two were not performed
because the children failed to attend the examination.
Statistical analyses were performed using the Statistical
Package for the Social Sciences program (SPSS), version 20.0.
Quantitative results are expressed as the average ± standard
deviation or as the median and range when distribution was
non-Gaussian. Prevalence was expressed as a percentage and
a 95% conﬁdence interval (CI) was applied. Unpaired t tests
were used to compare mean values between Hb S/D-Punjab
and Hb S-Korle Bu groups. Test results were considered signif-
icant when the probability of alpha error was ≤0.05.
The study was approved by the Ethics Research Committee
at the involved institutions (case No. 13327713.5.0000.5149). It
was conducted in accordance with the Helsinki Declaration as
revised in 2008. Patients and/or guardians were asked to sign
the informed consent form.Results
The incidence of Hb FSD at birth was 1:171,000 (95% CI:
1:120,000–1:299,000). Molecular analyses were applied to 2 0 1 6;3  8(3):240–246
samples from 19 out of the 21 children because as previously
mentioned, sample collection from two children was  not pos-
sible. The ages ranged from 2.8 to 16.2 years, with a median
of 8.9 years. Thirteen children were male (68.4%) and six were
female (31.6%).
Out of the 19 children, 11 children (ten families) were diag-
nosed with Hb S/D-Punjab disease and eight were diagnosed
with Hb S-Korle Bu. No other variants were found. Gender dis-
tribution in the Hb S/D-Punjab group was four females (36.4%)
and seven males (63.6%) and gender distribution in the Hb S-
Korle Bu group was two females (25%) and six males (75%). The
median age was 11 years (range: 2.8–16.2) in the Hb S/D-Punjab
group and 7.7 years (range: 3–13.7) in the Hb S-Korle Bu group.
All children of the Hb S/D-Punjab group were found to have
baseline Hb levels below 10 g/dL (average: 8.0 g/dL) and the
reticulocyte counts varied. The baseline values of the hema-
tologic tests and genetic results for each child are reported
in Table 1. Figure 2 compares the main results found in both
groups. The Hb S/D-Punjab group was found to have lower
average baseline Hb values and higher reticulocyte counts
than the Hb S-Korle Bu group (p-value <0.001 for both com-
parisons). Relative Hb F concentrations were higher in the
children of the Hb S/D-Punjab group (p-value = 0.001). Total
leukocyte and platelet counts were also higher in the Hb S/D-
Punjab group (p-value = 0.003 and p-value = 0.06, respectively).
Mean ratios between Hb S and Hb D concentrations were 1.06
and 1.14 in the Hb S/D-Punjab and Hb S-Korle Bu groups,
respectively (p-value = 0.61).
The coinheritance of alpha-thalassemia (/−3.7) was
detected in four children (two with Hb S/D-Punjab and
two with Hb S-Korle Bu). Mean corpuscular volume (MCV)
and mean corpuscular Hb (MCH) were signiﬁcantly lower
in children who co-inherited the alpha-thalassemia dele-
tion (p-value = 0.008 and p-value = 0.03, respectively). The Hb
S/D-Punjab group was analyzed separately: the MCVs of the
patients with and without-alpha thalassemia averaged 76.6 fL
and 85.9 fL, respectively (p-value = 0.001), while the MCHs aver-
aged 24.2 pg and 29.1 pg, respectively (p-value = 0.001).
In terms of the associated clinical ﬁndings, two (18.2%) of
the children in the Hb S/D-Punjab group had acute splenic
sequestration crises (ASSCs), and all 11 experienced at least
one acute pain episode. However, there were no ASSCs in the
Hb S-Korle Bu group, and three patients (37.5%) had at least
one acute pain episode reported as such in the patients’ med-
ical records. None of the children in the Hb S-Korle Bu group
received blood transfusions; however, seven (63.6%) children
in the Hb S/D-Punjab group received transfusions.
No child had an overt stroke. Mean Doppler TAMMX values
for Hb S/D-Punjab and Hb S-Korle Bu children were 131.1 cm/s
[standard error of the mean (SEM): 6.7] and 89.2 cm/s (SEM:
6.5), respectively (p-value = 0.001). All children were classiﬁed
as being at low risk for strokes.
Baseline oxygen saturation was lower in the Hb S/D-Punjab
group and signiﬁcantly differed from the Hb S-Korle Bu group.
Average values in the two groups were 91.9% and 97%, respec-
tively (p-value = 0.002). There were no deaths in the study
population.
Clinical treatment was also reviewed. All patients received
a prescription for antimicrobial prophylaxis, daily folic acid
supplements, and immunizations. Three (27.3%) of the
rev bras hematol hemoter. 2 0 1 6;3  8(3):240–246 243
Table 1 – Mean baseline hematological data and genetic results of 11 children with Hb S/DPunjab and eight children with
Hb S-Korle-Bu.
Id/Gender Hemoglobin
(g/dL)
Leukocytes
(×109/L)
Platelets
(×109/L)
Reticulocytes
(%)
Hb  F (%) Hb S (%) Hb D (%) S
haplotype/−3.7
thalb
Children with Hb S/DPunjab (n = 11)
1/F 7.2 13.9 347.7 4.0 13 48 37 CAR/−
2/M 7.9 16.1 431.8 14.7 13  45 39 ATP/−
3/F 6.8 13.7 368.0 8.7  14 38 44 BEN/−
4/M 6.8 18.0 552.0 7.5 4 44 37 CAR/−
5/F 8.3 15.2 300.2 9.5 22 41 35 BEN/−
6/Ma 8.6 11.2 335.0 3.9 23 33 40 BEN/+
7/F 9.5 12.6 353.8 3.2 16 47 39 BEN/−
8/Ma 8.9 15.0 454.0 6.4 21 36 40 BEN/−
9/M 8.4 13.6 432.2 10.3 10 40 46 CAR/+
10/M 6.2 13.3 308.8 8.7 16 39 35 CAR/−
11/M 9.5 11.2 430.9 5.9 25 37 36 BEN/−
Mean 8.0 14.0 392.2 7.5 16.1 40.7 38.9
Children with Hb S-Korle-Bu (n = 8)
1/M 11.7 12.2 397.3 1.8 6 58 34 CAR/+
2/M 12.8 10.8 366.9 1.2 9 45 45 CAR/−
3/M 11.5 7.1 326.6 1.0 7  45 42 CAR/−
4/F 12.8 7.7  257.0 1.1 6 59 33 BEN/−
5/F 13.2 10.1 275.6 0.4 9 41 48 CAR/+
6/M 12.3 11.4 331.7 0.6 6 39 52 CAR/−
7/M 12.0 14.3 407.9 1.3 4 50 44 CAR/−
8/M 11.8 10.5 266.3 0.8 8 39 50 CAR/−
Mean 12.3 10.5 328.7 1.0 6.9 47.0 43.5
F
T
ua Brothers.
b Co-inheritance (+ or −) of the alpha-thalassemia gene −3.7 (−3.7/).
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Table 2 – Clinical and laboratorial data in three children with Hb SD-Punjab and response to hydroxyurea.
Id/gender Age (years) at
start of HU
Clinical
indication
for HU
Dose
(mg/kg/day)
Duration
(months)
Before
hydroxyurea
After
hydroxyurea
Decreased
number  of
clinical events
Total Hb
(g/dL)/Hb
F (%)
Ret (%) Total Hb
(g/dL)/Hb
F (%)
Ret (%)
11/M 14 Severe vaso-
occlusive
pain episodes
20 8 9.5/26.7 6.1 11.1/34 0.4 Yes
9/M 6.6 Severe vaso-
occlusive
pain episodes
27 76 8.5/9.0 8.4 10.2/17 3.4 Yes
4/Ma 0.8 Anemia 15 36
8 Severe vaso-
occlusive
pain episodes
26 27 7.6/4.0 11.7 8.8/20 6.3 Yes
Id: identiﬁcation refers to numbers in Table 1; HU: hydroxyurea; Ret: reticulocyte count.
.0 g/d
of mua This child was given hydroxyurea in August 2005 because of Hb < 5
hematologist. The drug was restarted in September 2012, because 
children with Hb S/D-Punjab disease were found to have used
hydroxyurea, as indicated for recurring episodes of pain cri-
sis. All children presented increased total Hb and Hb F as well
as lower reticulocyte counts and fewer pain episodes after
hydroxyurea therapy. Another patient who  had also received
an indication for the use of hydroxyurea because of recurring
pain crises is likely to begin using the medication soon. Table 2
shows the data on the use of hydroxyurea.
Haplotyping of Hb S/D-Punjab showed that all patients pre-
sented haplotype I for the D-Punjab allele (+----+++, for the
eight analyzed polymorphic sites in the 5′->3′ direction). In
respect to the -globin gene cluster, six were Benin, four CAR,
and one had an atypical haplotype (+----+++, e.g., haplotype I
in homozygosis). Similarly, all Hb S-Korle Bu alleles presented
haplotype I. Seven had the S CAR haplotype and only one, the
S Benin haplotype.
Comparing hematological data between S CAR and S
Benin haplotypes within the Hb S/D-Punjab group of chil-
dren, Hb concentration (7.2 g/dL versus 8.6 g/dL, respectively)
and fetal Hb (10.8% versus 20.2%, respectively) were signif-
icantly higher for the Benin haplotype (p-value = 0.05 and
p-value = 0.01, respectively). No other data, including Doppler
TAMMX values, oxygen saturation, and number of transfu-
sions, were signiﬁcantly different between CAR and Benin
groups.
Discussion
Two variants with the IEF proﬁle of Hb D were identiﬁed:
D-Punjab and Korle Bu. The clinical and laboratory character-
istics of the two groups were very different.
Children with Hb S/D-Punjab disease presented many
different symptoms. This clinical course is similar to that
observed in children with homozygous Hb SS disease as has
already been reported in other studies.10,11,16,17,25 Oberoi et al.
evaluated ten patients aged between 1 and 19 years. All of
them presented with moderate or severe anemia (average:
6.8 g/dL) and at least one clinical complication related to theL. Hydroxyurea was withdrawn in July 2008 by his mother, not by the
ltiple episodes of vaso-occlusive pain.
disease, such as pain crisis, acute chest syndrome, gallstones,
avascular necrosis of femoral head, and recurrent infections.
Furthermore, eight patients required an average of three red
blood cell transfusions during their clinical follow-up period.11
In the present study, blood transfusions were required by
63.6% of patients.
Italia et al. reported on 15 patients with ages between 1 and
34 years. They classiﬁed only one patient as mild; two were
classiﬁed as having experienced moderate crises, and 12 were
found to have severe hemolytic anemia; these 12 presented
recurrent pain crises and required frequent transfusions.10
El-Kalla & Mathews evaluated nine patients aged between
3 and 10 years in the United Arab Emirates. They reported
pain crises of varying intensity, acute splenic sequestration
crises, and repeated infections in seven patients. The other
two children were asymptomatic, although anemic and with
increased reticulocyte counts.17 The largest sample size in the
literature was published by Patel et al. Of 42 Indian patients
with an average age of 22 years, 25 were considered to be
severe cases for presenting three or more  acute pain crises
and/or the need of two or more  blood transfusions in the year
prior to the study.25
The group of children with Hb S-Korle Bu disease did not
present clinical complications. Three children presented with
mild to moderate diffuse abdominal pain that was considered
secondary to the underlying disease. However, a pain crisis
is frequently inferred as the cause of abdominal pain when
signs and symptoms related to other etiologies (such as fever,
vomiting, and blood in the stools) are absent in children. Dur-
ing the crises, these children are generally assumed to have Hb
S/D-Punjab even if they have not been submitted to molecular
testing. Pain crises may be difﬁcult to distinguish from other
equally prevalent etiologies in children such as constipation
and functional abdominal pain.26 It is known that abdomi-
nal pain affects 38% of the school-aged pediatric population
weekly; no reliable biological markers clearly deﬁne a diag-
nosis of functional pain.27 In addition, few studies show that
the clinical course of Hb S-Korle Bu disease carriers may be
mild, with minor or even absent symptoms, but the number
er. 2 0
o
s
c
v
f
i
d
i
p
a
S
a
w
B
l
S
e
T
c
a
e
w
t
a
P
c
4
o
d
e
r
y
l
h
s
d
t
b
b
p
r
i
e
b
t
i
w
a
e
p
t
t
B
i
frev bras hematol hemot
f patients and length of follow-up preclude a solid conclu-
ion. Some authors have compared these patients to sickle
ell trait carriers.7 Therefore, the exact deﬁnition of the Hb D
ariant that the patient has is important for the correct dif-
erential diagnosis of abdominal pain in children. It also aids
n decreasing both the unnecessary stigma against chronic
iseases and unnecessary treatments, such as the indiscrim-
nate use of powerful anti-inﬂammatory medications and
ainkillers.
There seems to be no reports available in the literature
bout transcranial Doppler examinations in children with Hb
D disease. In the present study, all children were found to be
t low risk for strokes. As expected, the mean value of TAMMX
as signiﬁcantly higher in Hb S/D-Punjab than in Hb S-Korle
u children because the Hb concentration was signiﬁcantly
ower in the former group.
Higher Hb F baseline percentages were observed in the Hb
/D-Punjab group; there was a statistically signiﬁcant differ-
nce from the values observed in the Hb S-Korle Bu group.
he inﬂuence of this percentage on decreasing symptoms in
hildren with Hb S/D-Punjab disease remains unclear. This
ssociation has been described in patients with Hb SS dis-
ase and has been explained by the fact that red blood cells
ith larger quantities of Hb F possess lower levels of Hb S;
herefore, they have a lower chance of sickling, and as a result,
 lower probability of experiencing clinical manifestations.28
atel et al. found higher Hb F concentrations to be asso-
iated with a lower frequency of acute pain crises in the
2 patients with Hb S/D-Punjab disease.25 Meanwhile, three
ther studies failed to ﬁnd this association; however, they
id include much smaller sample populations than Patel
t al. The other studies included ﬁve, nine, and 15 patients,
espectively.9,10,17
Three children with the Hb S/D-Punjab variant took hydrox-
urea, and all children experienced signiﬁcant clinical and
aboratory improvements. In children with Hb SS, the use of
ydroxyurea has been determined to be safe and to provide
atisfactory results.29 In patients with Hb SD disease, the
ata on the efﬁcacy and safety of this medication are limited
o isolated cases19 and to a few studies with a larger num-
er of cases. Out of the ten children included in the study
y Oberoi et al., ﬁve received hydroxyurea to treat recurrent
ain episodes and/or severe anemia. Their follow-up periods
anged from 6 to 50 months. In all cases, there was a decrease
n the number of pain crises and a lack of signiﬁcant side
ffects.11 The largest cohort included 20 Indian patients aged
etween 1 and 45 years who took hydroxyurea for at least
wo years. Decreased frequencies of crises and interruptions
n transfusions were recorded for all patients. No side effects
ere observed.18
Haplotype I is the commonest type of D-Punjab allele in
lmost all ethnic populations so far described.6,14,15,30 The
xception is Thailand, where haplotype II was found in nine
atients from ﬁve families.31 So it is impossible to trace back
he origin of the allele in the population of this study. Haplo-
ypes for the Hb Korle Bu allele have not been described yet.
ecause all children in the present study are also type I, it
s improbable that the origin of the allele will be determined
or sure. It would be interesting to know whether the same 1 6;3  8(3):240–246 245
haplotype is present in Western Africa where the mutation
seemingly originated.5
As far as is known from international reports, the present
study demonstrated for the ﬁrst time that, within the Hb S/D-
Punjab group, children with the S Benin haplotype had higher
total Hb concentrations and higher relative concentrations of
fetal Hb than children with the S CAR haplotype.
The limitations of the present study include the fact that
it was a retrospective analysis and a low number of patients
were involved. These factors limit conclusions regarding the
incidence of clinical complications in cases of Hb S/D-Punjab
and Hb S-Korle Bu disease as well as a reliable evaluation of the
late-onset effects of the use of hydroxyurea. Furthermore, had
high performance liquid chromatography (HPLC) been used
as the primary screening test at PTN-MG, children with Hb S-
Korle Bu would not be classiﬁed as having Hb SD,  but instead
as having an unknown variant within the HPLC window of Hb
A2/Hb E.
In conclusion, this is the ﬁrst study in Brazil to evaluate
children with Hb SD disease detected at birth by IEF. It offers
a clear description of two variants: Hb S/D-Punjab and Hb S-
Korle Bu. Early newborn screening and the systematic genetic
study of Hb D variants are useful in treating patients and in
informing the family members about the prognosis of each
variant. Children with Hb S/D-Punjab have a clinical course
similar to those with Hb SS disease. The subgroup with the S
CAR haplotype have lower total Hb concentrations and lower
relative Hb F concentrations than those with the S Benin hap-
lotype, but the limited number of patients precludes deﬁnitive
conclusions. In contrast, the clinical course and laboratory
data in children with Hb S-Korle Bu appear to be similar to
those in children with the sickle cell trait, but caution should
be taken with this statement, considering the limited number
of children and short follow-up thus far reported.
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